GNI GNI GROUP LTD.

Contact Us
About Us
  • About Us TOP
  • Message
  • Business Model
  • Main Products
  • Management Policy
  • Company Overview
  • Board of Directors
  • Main Group Structure
  • Office
  • Corporate governance
R&D
  • R&D TOP
  • Pipeline
  • Discovery Research
  • Research publications
Investor Relations
  • Investor Relations TOP
  • IR News
  • Information
  • IR Materials
  • IR Calendar
  • IR Email Subscription
  • Electronic Public Notices
Sustainability/ESG
  • Sustainability/ESG TOP
  • Sustainability Initiatives
  • ESG Data
Contact Us
Site Map
Privacy Policy
Terms of Use
ソーシャルメディアポリシー

2011's Information

トップページInformation2011年
2011/12/28
Notice for Large Volume Exercise of the 35th Round of Stock Options
2011/12/19
Notice for Large Volume Exercise of the 35th Round of Stock Options
2011/12/16
Shanghai Genomics received research subsidy for F647 development from Shanghai Pudong New Area Government
2011/12/14
Notice for Large Volume Exercise of the 35th Round of Stock Options
2011/12/12
Notice for Large Volume Exercise of the 35th Round of Stock Options
2011/12/07
Notice of Payment for the 35th Round of Stock Options
2011/11/21
GNI Announces Third-Party Allotment and the Issuance of the 35th Round of Stock Options with Moving Strike
2011/10/31
SAPA-President Forum
2011/09/22
China SFDA Approves F647/Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis
2011/09/15
World Orphan Drug Congress
  • 1
  • 2
  • 3
  • >
画像

GNI

About Us
Message
Business Model
Main Products
Management Policy
Company Overview
Board of Directors
Main Group Structure
Office
Corporate Governance Policy
Investor Relations
IR News
IR Materials
IR Calendar
Electronic Public Notices
IR Email Subscription
R&D
Pipeline
Discovery Research
Research publications
Sustainability/ESG
Sustainability Initiatives
ESG Data
Contact Us
Career
Site Map
Privacy Policy
Terms of Use
Social Media Policy
Site Map
Privacy Policy
Terms of Use
Social Media Policy

© GNI Group Ltd. All Rights Reserved.